Dynavax Technologies Corporation Logo

Print Print page   Email Email page   PDF Download PDF    Add to Briefcase
« Previous Release | Next Release »



Dynavax to Present at the 31st Annual J.P. Morgan Healthcare Conference

BERKELEY, CA -- (Marketwire) -- 12/17/12 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 7, 2013 at 6:00 p.m. Eastern Time (3:00 p.m. Pacific Time).

Dino Dina, M.D., Chief Executive Officer of Dynavax, will provide a company overview. To access the slide presentation, live webcast, and subsequent archived recording, please visit Dynavax's website at http://investors.dynavax.com/newsevents.cfm.

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Dynavax's lead product candidate is HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.

Contact:

Michael Ostrach

Vice President and Chief Business Officer

510-665-7257

Email Contact



Source: Dynavax Technologies

News Provided by Acquire Media

Close window | Back to top